| Customization: | Available |
|---|---|
| Dossier: | Ctd |
| Transport Package: | Free |
|
Still deciding? Get samples of $ !
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
| Generic Name | Linagliptin Tablets 5mg |
| Strength | 5mg |
| Packing | 30tabs/box |
| Origin | China |
This product is light red round double convex, beveled edge film coating.
This product is suitable for the treatment of type 2 diabetes.
monotherapy
This product is used as an adjunct to diet control and exercise to improve blood sugar control in patients with type 2 diabetes.
Used in combination with metformin hydrochloride
When metformin hydrochloride alone is not effective in controlling blood sugar, this product can be used in combination with metformin hydrochloride to improve blood sugar control in patients with type 2 diabetes on the basis of diet and exercise.
Used in combination with metformin hydrochloride and sulfonylureas
When the combination of metformin hydrochloride and sulfonylureas still fails to effectively control blood sugar, this product can be used in combination with metformin hydrochloride and sulfonylureas to improve blood sugar control in type 2 diabetes patients on the basis of diet and exercise.
Matters needing attention:
pancreatitis
Patients were informed that postmarketing reports of acute pancreatitis, including fatal pancreatitis, had been received after the launch of Ligagliptin tablets. Inform the patient to carefully watch for potential signs and symptoms of pancreatitis, such as severe persistent abdominal pain, sometimes radiating to the back, with or without vomiting, which is the hallmark symptom of acute pancreatitis. If pancreatitis is suspected, stop taking lipliptin tablets immediately and contact your doctor to take appropriate action. When patients with a history of pancreatitis take ligagliptin tablets, it is uncertain whether they increase the risk of pancreatitis.
In combination with drugs known to cause hypoglycemia
Insulin stimulants and insulin are known to cause hypoglycemia. In one clinical trial, the combination of ligagliptin and insulin secreting agents (e.g., sulfonylureas) caused a higher incidence of hypoglycemia than placebo. The combination of rigliptin and insulin is associated with a higher incidence of hypoglycemia in patients with severe renal insufficiency. Therefore, when used in combination with rigliptin, a lower dose of an insulin-stimulating drug or insulin is required to reduce the risk of hypoglycemia.
){kind=link}